ASXC: AI 评分 53/100 — AI 分析 (4月 2026)

Asensus Surgical, Inc. is a medical device company focused on enhancing minimally invasive surgery through robotics. Their Senhance Surgical System aims to digitize the interface between surgeons and patients, improving surgical outcomes.

Key Facts: AI Score: 53/100 Sector: Healthcare

公司概况

概要：

Asensus Surgical, Inc. develops and sells medical device robotics, including the Senhance Surgical System, to enhance minimally invasive surgery. The company aims to improve surgical outcomes through digitized interfaces and clinical intelligence, operating in the competitive medical device market across the United States, Europe, and Asia.

ASXC是做什么的？

Asensus Surgical, Inc., founded in 2006 and headquartered in Durham, North Carolina, is a medical device company dedicated to revolutionizing minimally invasive surgery (MIS) through robotics. Formerly known as TransEnterix, Inc., the company rebranded in February 2021 to reflect its evolved focus on performance-guided surgery. Asensus Surgical develops, researches, and sells robotic medical devices designed to enhance surgical precision, visualization, and control. The company's flagship product is the Senhance Surgical System, a multi-port robotic surgery platform. This system allows surgeons to control up to four robotic arms and a camera during laparoscopic procedures. The Senhance system is designed to provide surgeons with enhanced dexterity, haptic feedback, and eye-tracking capabilities, aiming to improve surgical outcomes and reduce patient trauma. In addition to the Senhance system, Asensus Surgical offers a range of instruments and accessories, including 3mm diameter instruments, hooks, articulating instruments, and the Senhance ultrasonic system, an advanced energy device used for tissue ligation and division. Asensus Surgical operates in the United States, Europe, and Asia, targeting hospitals and surgical centers seeking to adopt advanced robotic surgery technologies. The company aims to establish a new standard of surgery by digitizing the interface between surgeons and patients, unlocking clinical intelligence, and enabling consistently superior outcomes.

ASXC的投资论点是什么？

Asensus Surgical operates in the growing robotic surgery market, with the Senhance Surgical System as its primary offering. The company's focus on enhancing minimally invasive surgery through digital interfaces and clinical intelligence presents a potential value driver. However, the company's negative profit margin of -914.5% and gross margin of -53.4% indicate significant challenges in achieving profitability. The company's market capitalization is approximately $0.09 billion. Upcoming catalysts include potential regulatory approvals and expansions into new markets. Potential risks include competition from established players in the robotic surgery market and the need for significant capital to fund ongoing operations and research and development.

ASXC在哪个行业运营？

Asensus Surgical operates within the medical device industry, specifically in the robotic surgery segment. The industry is characterized by technological innovation, increasing demand for minimally invasive procedures, and a competitive landscape dominated by established players like Intuitive Surgical. The global robotic surgery market is projected to continue growing, driven by factors such as an aging population, rising healthcare expenditures, and advancements in robotic technology. Asensus Surgical aims to capture market share by offering a differentiated robotic surgery platform with enhanced features and capabilities.

Medical - Devices

Healthcare

ASXC有哪些增长机遇？

Expansion into new surgical specialties: Asensus Surgical can expand the application of the Senhance Surgical System into new surgical specialties beyond general surgery and gynecology. This includes exploring opportunities in areas such as urology, thoracic surgery, and pediatric surgery. The global surgical robotics market is expected to reach $14.7 billion by 2028, presenting a significant opportunity for Asensus Surgical to increase its market share by diversifying its product applications.
Geographic expansion: Asensus Surgical can expand its geographic footprint by targeting new markets in Asia, Latin America, and other regions with growing demand for advanced surgical technologies. This expansion can be achieved through strategic partnerships, distribution agreements, and direct sales efforts. Emerging markets offer significant growth potential due to increasing healthcare spending and a growing adoption of minimally invasive surgical techniques.
Development of new instruments and accessories: Asensus Surgical can invest in the development of new instruments and accessories for the Senhance Surgical System to enhance its capabilities and address a wider range of surgical procedures. This includes developing specialized instruments for specific surgical specialties, as well as advanced imaging and navigation technologies. Innovation in instruments and accessories can drive increased adoption of the Senhance system and generate recurring revenue streams.
Strategic partnerships and collaborations: Asensus Surgical can pursue strategic partnerships and collaborations with hospitals, research institutions, and other medical device companies to accelerate the development and commercialization of its products. These partnerships can provide access to new technologies, expertise, and distribution channels. Collaborations with leading medical centers can also help to validate the clinical benefits of the Senhance system and drive adoption among surgeons.
Integration of artificial intelligence and machine learning: Asensus Surgical can integrate artificial intelligence (AI) and machine learning (ML) technologies into the Senhance Surgical System to enhance surgical planning, execution, and post-operative analysis. This includes developing AI-powered tools for surgical navigation, real-time image analysis, and predictive analytics. The integration of AI and ML can improve surgical outcomes, reduce complications, and enhance the overall efficiency of the Senhance system.

Market capitalization of $0.09 billion reflects the company's current valuation in the market.
Negative profit margin of -914.5% indicates significant challenges in achieving profitability.
Gross margin of -53.4% suggests high costs associated with the company's products and services.
Beta of 1.38 indicates higher volatility compared to the overall market.
The company does not currently offer a dividend, reflecting a focus on reinvesting earnings for growth.

ASXC提供哪些产品和服务？

Develops and sells the Senhance Surgical System, a multi-port robotic surgery platform.
Offers instruments and accessories for the Senhance system, including 3mm and 5mm hooks.
Provides the Senhance ultrasonic system for tissue ligation and division.
Digitizes the interface between surgeons and patients.
Pioneers performance-guided surgery through clinical intelligence.
Enhances minimally invasive surgery (MIS) through robotics.

ASXC如何赚钱？

Sales of the Senhance Surgical System to hospitals and surgical centers.
Recurring revenue from the sale of instruments and accessories.
Service and maintenance contracts for the Senhance system.
Potential revenue from future software upgrades and AI-powered features.

Hospitals and surgical centers seeking to adopt advanced robotic surgery technologies.
Surgeons performing minimally invasive surgical procedures.
Patients undergoing surgical procedures that can benefit from robotic assistance.

Proprietary robotic surgery technology with patents protecting key innovations.
Established relationships with hospitals and surgeons using the Senhance system.
Potential for network effects as more surgeons adopt the Senhance system and share best practices.
Focus on performance-guided surgery through digitized interfaces and clinical intelligence.

什么因素可能推动ASXC股价上涨？

Upcoming: Potential regulatory approvals for new features and indications of the Senhance Surgical System.
Ongoing: Expansion into new surgical specialties, such as urology and thoracic surgery.
Ongoing: Strategic partnerships with hospitals and research institutions to validate the clinical benefits of the Senhance system.

ASXC的主要风险是什么？

Potential: Intense competition from established players in the robotic surgery market, such as Intuitive Surgical.
Ongoing: The company's negative profit margin and gross margin pose a risk to its financial sustainability.
Potential: Regulatory hurdles and changing healthcare policies could impact the commercialization of the Senhance system.
Potential: Economic downturns and reduced healthcare spending could affect demand for robotic surgery technologies.

ASXC的核心优势是什么？

Innovative Senhance Surgical System with unique features.
Focus on performance-guided surgery and clinical intelligence.
Potential for improved surgical outcomes and reduced patient trauma.
Expansion into new surgical specialties and geographic markets.

ASXC的劣势是什么？

Negative profit margin and gross margin.
Limited market share compared to established competitors.
Need for significant capital investment in research and development.
Dependence on regulatory approvals for product commercialization.

ASXC有哪些机遇？

Growing demand for minimally invasive surgical procedures.
Increasing adoption of robotic surgery technologies.
Potential for strategic partnerships and collaborations.
Integration of artificial intelligence and machine learning.

ASXC面临哪些威胁？

Intense competition from established players in the robotic surgery market.
Technological advancements by competitors.
Regulatory hurdles and changing healthcare policies.
Economic downturns and reduced healthcare spending.

ASXC的竞争对手是谁？

AADI Bioscience, Inc. — Focuses on precision oncology medicines. — (AADI)
Berkeley Lights, Inc. — Provides a platform for cell line development. — (BLI)
iCAD, Inc. — Offers cancer detection and therapy solutions. — (ICAD)
Immuno Diagnostics, Inc. — Specializes in allergy and autoimmune diagnostics. — (IMDX)
Jounce Therapeutics, Inc. — Develops cancer immunotherapies. — (JNCE)

Key Metrics

MoonshotScore: 53/100

Company Profile

CEO: Anthony Fernando
Headquarters: Durham, US
Employees: 207
Founded: 1991

AI Insight

AI analysis pending for ASXC

常见问题

What does Asensus Surgical, Inc. do?

Asensus Surgical, Inc. is a medical device company focused on enhancing minimally invasive surgery (MIS) through its Senhance Surgical System. This robotic surgery platform aims to digitize the interface between surgeons and patients, providing enhanced precision, visualization, and control during surgical procedures. The company's business model revolves around the sale of the Senhance system, instruments, and accessories to hospitals and surgical centers, along with ongoing service and maintenance contracts. Asensus Surgical aims to establish a new standard of surgery by unlocking clinical intelligence and enabling consistently superior outcomes.

What do analysts say about ASXC stock?

AI analysis is pending for ASXC. Generally, analyst opinions on medical device companies like Asensus Surgical take into account factors such as market growth potential, technological innovation, regulatory approvals, and competitive positioning. Key valuation metrics include revenue growth, gross margin, and profitability. Growth considerations often focus on the company's ability to expand into new markets, develop new products, and secure strategic partnerships. The absence of analyst ratings at this time limits the ability to provide a comprehensive summary of analyst consensus.

What are the main risks for ASXC?

Asensus Surgical faces several risks inherent to the medical device industry, including intense competition from established players like Intuitive Surgical, the need for significant capital investment in research and development, and dependence on regulatory approvals for product commercialization. The company's negative profit margin and gross margin pose a significant financial risk, requiring substantial improvements in operational efficiency and revenue generation. Additionally, economic downturns and changes in healthcare policies could affect demand for robotic surgery technologies and impact the company's financial performance. Patent expiration and potential product liability claims also represent ongoing risks.

How does Asensus Surgical, Inc. manage regulatory risks?

Asensus Surgical mitigates regulatory risks by maintaining a robust quality management system, adhering to strict regulatory guidelines, and proactively engaging with regulatory agencies. The company invests in comprehensive testing and validation processes to ensure the safety and efficacy of its products. Asensus Surgical also monitors changes in regulatory requirements and adapts its processes accordingly. Furthermore, the company seeks regulatory approvals in multiple markets to diversify its geographic risk exposure. The company's regulatory strategy is crucial for maintaining market access and ensuring compliance with applicable laws and regulations.

What revenue streams does Asensus Surgical, Inc. have in healthcare?

Asensus Surgical's revenue streams primarily consist of sales of the Senhance Surgical System, recurring revenue from the sale of instruments and accessories, and service and maintenance contracts. The company generates revenue from hospitals and surgical centers that adopt the Senhance system for minimally invasive surgical procedures. Revenue is also derived from the sale of specialized instruments, such as 3mm diameter instruments and articulating instruments, which are used in conjunction with the Senhance system. Furthermore, Asensus Surgical generates revenue from service and maintenance contracts that provide ongoing support and upgrades for the Senhance system. Future revenue streams may include software upgrades and AI-powered features.